Müller, Frank

[["dc.bibliographiccitation.firstpage","4415"],["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","International Journal of Environmental Research and Public Health"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Happle, Christine"],["dc.contributor.author","Dopfer, Christian"],["dc.contributor.author","Ernst, Diana"],["dc.contributor.author","Kleinert, Evelyn"],["dc.contributor.author","Vakilzadeh, Annabelle"],["dc.contributor.author","Hellms, Susanne"],["dc.contributor.author","Evlampidou, Iro"],["dc.contributor.author","Hillermann, Nele"],["dc.contributor.author","Schmidt, Reinhold E."],["dc.contributor.author","Behrens, Georg M. N."],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Wetzke, Martin"],["dc.contributor.author","Jablonka, Alexandra"],["dc.date.accessioned","2020-12-10T18:47:08Z"],["dc.date.available","2020-12-10T18:47:08Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3390/ijerph16224415"],["dc.identifier.eissn","1660-4601"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17106"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78652"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","1660-4601"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Pediatric Healthcare Utilization in a Large Cohort of Refugee Children Entering Western Europe During the Migrant Crisis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","403"],["dc.bibliographiccitation.firstpage","403"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Infectious Diseases"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Dopfer-Jablonka, Alexandra"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Cossmann, Anne"],["dc.contributor.author","Stankov, Metodi V."],["dc.contributor.author","Behrens, Georg M. N."],["dc.contributor.author","Hummers, Eva"],["dc.contributor.author","Heesen, Gloria"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Roder, Sascha"],["dc.contributor.author","Klawonn, Frank"],["dc.contributor.author","Vahldiek, Kai"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Kallusky, Jonathan"],["dc.contributor.author","Falk, Christine S."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Heinemann, Stephanie"],["dc.date.accessioned","2022-04-29T07:33:23Z"],["dc.date.accessioned","2022-08-12T12:57:45Z"],["dc.date.available","2022-04-29T07:33:23Z"],["dc.date.available","2022-08-12T12:57:45Z"],["dc.date.issued","2022-04-25"],["dc.date.updated","2022-07-29T12:00:25Z"],["dc.description.abstract","Background\r\n Immunocompromised people (ICP) and elderly individuals (older than 80 years) are at increased risk for severe coronavirus infections. To protect against serious infection with SARS-CoV-2, ICP are taking precautions that may include a reduction of social contacts and participation in activities which they normally enjoy. Furthermore, for these people, there is an uncertainty regarding the effectiveness of the vaccination. The COVID-19 Contact (CoCo) Immune study strives to characterize the immune response to COVID-19 vaccination in immunocompromised, elderly people, and patients with hematological or oncological diseases. The study uses blood-based screenings to monitor the humoral and cellular immune response in these groups after vaccination. Questionnaires and qualitative interviews are used to describe the level of social participation.\r\n \r\n \r\n Methods\r\n The CoCo Immune Study is a mixed methods prospective, longitudinal, observational study at two large university hospitals in Northern Germany. Starting in March 2021, it monitors anti-SARS-CoV-2 immune responses and collects information on social participation in more than 600 participants, at least 18 years old. Inclusion criteria and subcohorts: Participants with (1) regularly intake of immunosuppressive medication (ICP-cohort) or (2) age ≥ 80 years (80 + -cohort). Additionally, patients with current or former (3) myeloid, (4) lymphatic disease or (5) solid tumor under checkpoint inhibition (3–5: HO-cohort). Exclusion criteria: (1) refusal to give informed consent, (2) contraindication to blood testing, (3) inability to declare consent. Participants complete a questionnaire at four different time points: prior to full vaccination, and 1, 6 and 12 months after completed vaccination. In addition, participants draw blood samples themselves or through a local health care provider and send them with their questionnaires per post at the respective time points after vaccination. Patients of the HO cohort dispense additional blood samples at week 3 to 12 and at month 6 to 9 after 2nd vaccination to gain additional knowledge in B and T cell responses. Selected participants are invited to qualitative interviews about social participation.\r\n \r\n \r\n Discussion\r\n This observational study is designed to gain insight into the immune response of people with weakened immune systems and to find out how social participation is affected after COVID-19 vaccination.\r\n Trial registration: This study was registered with German Clinical Trial Registry (registration number: DRKS00023972) on 30th December 2020."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","BMC Infectious Diseases. 2022 Apr 25;22(1):403"],["dc.identifier.doi","10.1186/s12879-022-07347-w"],["dc.identifier.pmid","35468758"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106987"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112723"],["dc.language.iso","en"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.eissn","1471-2334"],["dc.relation.issn","1471-2334"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","SARS-CoV-2"],["dc.subject","COVID-19"],["dc.subject","Pandemic"],["dc.subject","Humoral and cellular immunity"],["dc.subject","Immunocompromised people"],["dc.subject","Elderly"],["dc.subject","Hematology"],["dc.subject","Solid tumor"],["dc.subject","Checkpoint inhibition"],["dc.subject","Serological testing"],["dc.subject","Coronavirus"],["dc.subject","Social participation"],["dc.subject","Immunogenicity"],["dc.title","SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology"],["dc.contributor.author","Niewolik, Jacqueline"],["dc.contributor.author","Mikuteit, Marie"],["dc.contributor.author","Cossmann, Anne"],["dc.contributor.author","Vahldiek, Kai"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Müller, Frank"],["dc.contributor.author","Schröder, Dominik"],["dc.contributor.author","Heinemann, Stephanie"],["dc.contributor.author","Behrens, Georg M. N."],["dc.contributor.author","Dopfer-Jablonka, Alexandra"],["dc.contributor.author","Steffens, Sandra"],["dc.contributor.author","Grimmelmann, Imke"],["dc.creator.author","Jacqueline Niewolik"],["dc.creator.author","Marie Mikuteit"],["dc.creator.author","Anne Cossmann"],["dc.creator.author","Kai Vahldiek"],["dc.creator.author","Ralf Gutzmer"],["dc.creator.author","Frank Müller"],["dc.creator.author","Dominik Schröder"],["dc.creator.author","Stephanie Heinemann"],["dc.creator.author","Georg M.N. Behrens"],["dc.creator.author","Alexandra Dopfer-Jablonka"],["dc.creator.author","Sandra Steffens"],["dc.creator.author","Imke Grimmelmann"],["dc.date.accessioned","2022-05-25T04:34:16Z"],["dc.date.available","2022-05-25T04:34:16Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: Immunogenicity of SARS-CoV-2 vaccines is modestly impaired in cancer patients due to a generally weakened immune system. Immune checkpoint inhibitors (ICI) are expected to enhance immune response. This has already been described to be the case in influenza vaccines, and first data about COVID-19 vaccines show a trend in this direction. Aim: We aimed to investigate the immune response of patients with melanoma under ICI therapy after COVID-19 vaccination. Patients and Methods: In the Skin Cancer Center Hanover (Germany), we recruited 60 patients with advanced melanoma who either received ICI therapy during or before the vaccination period. Serological blood analysis was performed using quantitative ELISA for Anti-SARS-CoV-2 spike protein 1 IgG antibodies. Results: We did not observe an enhanced humoral immune response in patients under active or past ICI therapy after COVID-19 vaccination. Nevertheless, there is a tendency of higher antibody levels when ICI therapy was received within the last 6 months before vaccination. Subgroup analysis revealed that patients in our study population under ongoing targeted therapy during vaccination period had significantly higher median antibody levels than patients without any active antitumor treatment. Conclusion: Melanoma patients under ICI therapy show comparable antibody response after SARS-CoV-2 vaccination to healthy health care professionals. This finding is independent of the timing of ICI therapy."],["dc.identifier.doi","10.1159/000524894"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108255"],["dc.language.iso","en"],["dc.relation","DEFEnse Against COVID-19 STudy"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.title","Immunogenicity of COVID-19 vaccination in melanoma patients under immune checkpoint blockade"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]